Immune-active microenvironment in SCCOHT: Rationale for therapy with immune checkpoint blockade.

被引：0
|
作者：
Van Oudenhove, Elke [1 ]
Jelinic, Petar [1 ]
Ricca, Jacob [2 ]
Narciso, Olvera [1 ]
Merghoub, Taha
Levine, Douglas A. [1 ]
Zamarin, Dmitriy [2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CLINICAL CANCER RESEARCH | 2018年 / 24卷 / 15期
关键词：
D O I：
10.1158/1557-3265.OVCA17-B26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B26
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [1] Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
    Jelinic, Petar
    Ricca, Jacob
    Van Oudenhove, Elke
    Olvera, Narciso
    Merghoub, Taha
    Levine, Douglas A.
    Zamarin, Dmitriy
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (07): : 787 - 790
  • [2] Epigenetic Modulation of the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade Therapy
    Menzel, Johannes
    Black, Joshua C.
    CANCER DISCOVERY, 2020, 10 (02) : 179 - 181
  • [3] Subsets of interferon signaling and response to immune checkpoint blockade.
    Lee, Daniel
    Horowitch, Brooke
    Ding, Min
    Martinez-Morilla, Sandra
    Aung, Thazin Nwe
    Ouerghi, Feriel
    Wang, Xueting
    Wei, Wei
    Damsky, William
    Sznol, Mario
    Kluger, Harriet M.
    Rimm, David L.
    Ishizuka, Jeffrey Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Effect of STING agonist on tumor immune microenvironment of non-inflamed lung cancer and efficacy of immune checkpoint blockade.
    Chon, Hongjae
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [5] Immune checkpoint blockade therapy
    Wieder, Thomas
    Eigentler, Thomas
    Brenner, Ellen
    Roecken, Martin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (05) : 1403 - 1414
  • [6] Epigenetic changes in T cells in response to immune checkpoint blockade.
    Goswami, Sangeeta
    Zhao, Hao
    Zhang, Xuejun
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
    Russell, Bonnie L.
    Sooklal, Selisha A.
    Malindisa, Sibusiso T.
    Daka, Lembelani Jonathan
    Ntwasa, Monde
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
    Li, Yaqi
    Liu, Jing
    Gao, Long
    Liu, Yuan
    Meng, Fang
    Li, Xiaoan
    Qin, F. Xiao-Feng
    IMMUNOLOGY LETTERS, 2020, 220 : 88 - 96
  • [9] Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade.
    Santomasso, Bianca
    Haggiagi, Aya
    Malani, Rachna
    Maher, Colleen Anne
    Holder, Jenessa N.
    Shames, Yelena
    Wilcox, Jessica
    Flynn, Jessica
    Briggs, Samuel
    Panageas, Katherine
    Callahan, Margaret K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] HIV-positive Kaposi sarcoma and immune checkpoint blockade.
    Galanina, Natalie
    Goodman, Aaron
    Cohen, Philip R.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
12345